Search

Changes to Formulary as of 14th January 2020:

BNF Category Number

Product/indication

Detail of change

8.1.5

Idelalisib

Added link to NICE TA604

4.9.3

Xeomin (botulinum neurotoxin type A)

Added as a RED drug and added link to NICE TA605

3.4.3

Lanadelumab

Added as a RED drug and added link to NICE TA606

2.8.2

Rivaroxaban 2.5mg tablets

Added as an AMBER Specialist Initiation drug and added link to NICE TA607

8.1.5

Ibrutinib

Added link to NICE TA608

8.1.5

Ramucirumab

Added link to NICE TA609

7.4.3

Pentosan polysulfate sodium

Added link to NICE TA610

8.1.5

Rucaparib

Added as a RED drug and added link to NICE TA611

8.1.5

Neratinib

Added as a RED drug and added link to NICE TA612

11.4.1

Fluocinolone acetonide intravitreal implant

Added link to NICE TA6113 and not approved for this indication

6

 

Added link to NICE NG145

1

 

Added link to NICE NG147

9.1.1.2

Iron Isomaltoside (Monofer®) injection

Added as RED drug

1.5.2

Budesonide (Cortiment® 9mg prolonged release tablets  in adults for induction of remission in patients with mild to moderate active ulcerative colitis (UC) where 5-ASA treatment is not sufficient.

Added as RED drug

5.3.1

Bictegravir 50mg/ Emtricitabine 200mg/Tenofovir alafenamide fumarate 25mg Film coated tablets (Biktarvy®) for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir

Added as RED drug

14.4

Gardasil 9® suspension for injection Human pappilomavirus 9-valent vaccine for Recurrent Laryngeal Papillomatosis (unlicensed indication)

Added as RED drug

5.3.4

Zanamivir 10mg/ml solution for infusion

Added as RED drug

4.7.2

Methadone in palliative care

Changed from RED to AMBER Specialist Initiation/Recommendation with note that use in pain management should be under the advice of palliative care

9.6.7

Renavit

Changed from RED to AMBER Specialist Initiation/Recommendation for  Renal dialysis patients only

1.5.1

Review of oral Mesalazine brands currently included in formulary

·      Asacol removed from formulary as Octasa has replaced this.

·      All formulations of Salofalk and Octasa to formulary added to formulary.

3.7

Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor for Cystic Fibrosis

Added as RED drugs

4.1.1

Melatonin oral solution 5mg/5ml Propylene glycol and alcohol free

Added as AMBER SHARED CARE drug

6.4.1.2

Progesterone pessaries – clarification for formulary status and indications approved for

Confirmed formulary status as RED for IVF use and to support the pregnancies of woman who have a history of miscarriage or premature labour as per NICE NG 25.

11.8.2.2

Apraclonidine 0.5% and 1% eye drops – clarification of formulary status and RAG status

·      Both 0.5% and 1% to remain as AMBER Specialist Initiation when used off-label in complex glaucoma when all other options failed to preserve sight on unlicensed basis

·      0.5% when used as per license prior to laser treatment or surgery to be RED.

·      1% when used as per license in Theatre to be RED.

13.9

Eflornithine cream – clarification of current RAG status

Changed to RED drug and to be used only in line with laser therapy.

2.7.2

Midodrine for use in postural hypotension

Changed to AMBER specialist initiation.

6.5.2.2

Tolvaptan (Samsca® for non-chemo related SIADH

Added as RED drug for max 10 day course and not for long term use.

8.3.4.2

Triptorelin

Added as Amber Specialist Initiation for all indications including precocious puberty

12.1.1

Flumetasone 0.02% with Clioquinol 1% for Otitis Externa

Added as GREEN drug.

4.1.1

Chloral Hydrate 1g/5mL oral solution       

 

Added to formulary 1g/5ml as RED drug with note that standard strength recommended by RCPCH in children. Removed 500mg/5ml from formulary.

6.3.1

Hydrocortisone 5mg/5mL oral solution       

Added this strength to formulary as AMBER SI with note that standard strength recommended by RCPCH in children. To Retain 10mg/5ml for now as used NoT and in adults

1.3.5

Omeprazole 20mg/5ml oral solutions

Added to formulary as AMBER SI with note that standard strength recommended by RCPCH in children. To be only for children with narrow bore feeding tubes or those requiring a dose <5mg. Lansoprazole fast tabs or omeprazole MUPS should be used in all other patients.

4.8.1

Phenobarbital (alcohol free) 50mg/5mL oral solution 

Replaced 20mg/ml with 50mg/ml strength with note that standard strength recommended by RCPCH in children.

4.3.3

Sertraline 50mg/5mL  oral solution

 

Added 50mg/5ml as AMBER SI to formulary with note that standard strength recommended by RCPCH in children.

9.2.1

Sodium chloride 5mmol/mL oral solution       

Added to formulary 5mmol/ml as AMBER SI with note that standard strength recommended by RCPCH in children. Retain 1mmol/ml for now as licensed product.

2.2.3

Spironolactone 50mg/5mL oral liquid

                   

Added to formulary with note that standard strength recommended by RCPCH in children. Removed 5mg/5ml, 25mg/5ml and 100mg/5ml from formulary. Retained 10mg/5ml as in NoT formulary

8.2.2

Tacrolimus 5mg/5ml oral liquid    

Added to formulary as RED drug with note that standard strength recommended by RCPCH in children

4.2.2

Antipsychotic depot injections

Added sentence to formulary that “If the transfer of care was made prior to 11/7/2019 then this drug was considered as amber specialist initiation and does not need to be referred back to establish shared care.  A shared care agreement is required for any transfer from 11/7/2019 onwards”

Changes to Formulary as of 24th December 2019:

BNF Category Number

Product/indication

Detail of change

15.1.1.

Ketamine in Palliative Care

Changed from AMBER Shared Care to RED

13.2

Emollients and fire risk

Added link to https://psnc.org.uk/our-news/new-video-highlights-the-potential-fire-hazard-with-paraffin-based-skin-products/

11.4.1

Fluocinolone

Added link to NICE TA590

5.3.2.2

Letermovir

Added as RED drug and added link to NICE TA591

8.2.4

Cemiplimab

Added as RED drug and added link to NICE TA592

8.1.5

Ribociclib

Added link to NICE TA593

8.1.5

Brentuximab vedotin

Added link to NICE TA594

8.1.5

Dacomitinib

Added as RED drug and added link to NICE TA595

6.1.2.3

Dapagliflozin with insulin in type 1 diabetes

Added as AMBER specialist initiation drug for this indication and added link to NICE TA597

8.1.5

Olaparib

Added link to NICE TA598

9.2.1.1

Sodium zirconium

Added as RED drug and added link to NICE TA599

8.1.5

Pembrolizumab

Added link to NICE TA600

5.1.7

Bezlotoxumab

Added as NOT APPROVED and added link to NICE TA601

8.1.5

Pomalidomide

Added link to NICE TA602

8.2.4

Lenalidomide

Added link to NICE TA603

13.8.1

Ingenol mebutate

Added link to MHRA DSU

8.2.4

Nivolumab

Added link to MHRA DSU

8.1.5

Carfilzomib

Added link to MHRA DSU

14.4

Yellow fever vaccine

Added link to MHRA DSU

3.2.2

Montelukast

Added link to MHRA DSU

7.4.3

Pentosan

Added link to MHRA DSU

8.2.4

Fingolimod

Added link to MHRA DSU

6.4.1.1

HRT

Added link to MHRA DSU

8.1.5

Carfilzomib

Added link to MHRA DSU

4.5.1

Naltrexone/Bupropion (Mysimba)

Added link to MHRA DSU

8.1.5

Daratumumab

Added link to MHRA DSU

13

 

Harmonised Chapter 13 added

11

 

Harmonised Chapter 11 added

4

Methadone

Changed to RED for opioid dependence

4

Buprenorphine

Changed to RED for opioid dependence

13.2.1

Aveeno

Removed from formulary. Alternative = Zeroveen

4.3.3

Paroxetine

Added as GREY drug

6.5.1.2

Meriofert

Added as additional brand that is available to Menopur

8.3.4.3

Pasireotide

Changed from NOT APROVED to RED drug

4.8.1

MCT oil

Added as NOT APPROVED